Trial Profile
A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-Grade Cervical Intraepithelial Neoplasia (CIN1)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary) ; Hexyl aminolevulinate (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors PhotoCure
- 14 Oct 2021 This trial has been completed in France (Global end date: 10 Jan 2012).
- 26 Jun 2012 Actual patient number changed from 70 to 83 as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.